Serum and urine biomarkers for human renal cell carcinoma

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Pastore, A L ^a   Palleschi, G ^a   Silvestri, L ^a   Moschese, D ^a   Ricci, S ^b   Petrozza, V ^a   Carbone, A ^a   Di Carlo, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 1; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; HEAT SHOCK PROTEIN 27; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; KIDNEY INJURY MOLECULE 1; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 22; OSTEOPONTIN; PERILIPIN; PYRUVATE KINASE TYPE M2; SERUM AMYLOID A; THYMIDINE KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BODY FLUID; CANCER CLASSIFICATION; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; PRIORITY JOURNAL; RISK FACTOR; SERODIAGNOSIS; URINALYSIS; BLOOD; KIDNEY TUMOR; URINE;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 84928248709     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/251403     Document Type: Article

References (87)

1. C. T. Lee, J. Katz, P. A. Fearn, and P. Russo, "Mode of presentation of renal cell carcinoma provides prognostic information," Urologic Oncology, vol. 7, no. 4, pp. 135-140, 2002.
2. F. Levi, J. Ferlay, C. Galeone et al., "The changing pattern of kidney cancer incidence and mortality in Europe," BJU International, vol. 101, no. 8, pp. 949-958, 2008.
3. L. Lipworth, R. E. Tarone, and J. K. McLaughlin, "The epidemiology of renal cell carcinoma," Journal of Urology, vol. 176, no. 6, pp. 2353-2358, 2006.
4. H. van Poppel, L. da Pozzo, W. Albrecht et al., "A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma," European Urology, vol. 59, no. 4, pp. 543-552, 2011.
5. W. C. Huang, E. B. Elkin, A. S. Levey, T. L. Jang, and P. Russo, "Partial nephrectomy vs. radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes" Journal of Urology, vol. 181, no. 1, pp. 55-61, 2009.
6. E. H. Kim, Y. S. Tanagho, S. B. Bhayani, N. E. Saad, B. M. Benway, and R. S. Figenshau, "Percutaneous cryoablation of renal masses:Washington University experience of treating 129 tumours," BJU International, vol. 111, no. 6, pp. 872-879, 2013.
7. T. M. Wah, H. C. Irving, W. Gregory, J. Cartledge, A. D. Joyce, and P. J. Selby, "Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours," BJU International, vol. 113, no. 3, pp. 416-428, 2014.
8. F. Audenet, D. R. Yates, G. Cancel-Tassin, O. Cussenot, and M. Roupret, "Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine," BJU International, vol. 109, no. 12, pp. 1864-1870, 2012.
9. T. Pischon, P. H. Lahmann, H. Boeing et al., "Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)," International Journal of Cancer, vol. 118, no. 3, pp. 728-738, 2006.
10. C. R. Daniel, A. J. Cross, B. I. Graubard et al., "Large prospective investigation ofmeat intake, relatedmutagens, and risk of renal cell carcinoma,"The American Journal of Clinical Nutrition, vol. 95, no. 1, pp. 155-162, 2012.
11. Y. Xu, Y. Qi, J. Zhang et al., "The impact of smoking on survival in renal cell carcinoma: a systematic review and meta-analysis," Tumor Biology, vol. 35, no. 7, pp. 6633-6640, 2014.
12. K. M. Sanfilippo, K. M. McTigue, C. J. Fidler et al., "Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women," Hypertension, vol. 63, no. 5, pp. 934-941, 2014.
13. J. Hu, Y. Mao, K. White et al., "Renal cell carcinoma and occupational exposure to chemicals in Canada," Occupational Medicine, vol. 52, no. 3, pp. 157-164, 2002.
14. A. Schwarz, S. Vatandaslar, S. Merkel, and H. Haller, "Renal cell carcinoma in transplant recipients with acquired cystic kidney disease," Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 750-756, 2007.
15. B. Bausch, C. Jilg, S. Gläsker et al., "Renal cancer in von Hippel-Lindau disease and related syndromes," Nature Reviews Nephrology, vol. 9, no. 9, pp. 529-538, 2013.
16. C. G. Przybycin, C. Magi-Galluzzi, and J. K. McKenney, "Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens," Advances in Anatomic Pathology, vol. 20, no. 4, pp. 245-263, 2013.
17. H. L. Kim, A. S. Belldegrun, D. G. Freitas et al., "Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis," Journal of Urology, vol. 170, no. 5, pp. 1742-1746, 2003.
18. H. B. Palsdottir, S. Hardarson, V. Petursdottir et al., "Incidental detection of renal cell carcinoma is an independent prognostic marker: results of a long-term, whole population study," The Journal of Urology, vol. 187, no. 1, pp. 48-53, 2012.
19. O. Hélénon, J. M. Correas, C. Balleyguier,M. Ghouadni, and F. Cornud, "Ultrasound of renal tumors," European Radiology, vol. 11, no. 10, pp. 1890-1901, 2001.
20. M. J. Leveridge, P. J. Bostrom, G. Koulouris, A. Finelli, and N. Lawrentschuk, "Imaging renal cell carcinoma with ultrasonography, CT and MRI," Nature Reviews Urology, vol. 7, no. 6, pp. 311-325, 2010.
21. T. Lebret, J. E. Poulain, V. Molinie et al., "Percutaneous core biopsy for renal masses: indications, accuracy and results," Journal of Urology, vol. 178, no. 4, part 1, pp. 1184-1188, 2007.
22. M. K. Gospodarowicz, D. Miller, P. A. Groome, F. L. Greene, P. A. Logan, and L. H. Sobin, "The process for continuous improvement of the TNM classification," Cancer, vol. 100, no. 1, pp. 1-5, 2004.
23. S. P. Kim, A. L. Alt, C. J. Weight et al., "Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results froma large, single institution cohort," Journal of Urology, vol. 185, no. 6, pp. 2035-2039, 2011.
24. G. Novara, V. Ficarra, A. Antonelli et al., "Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed" European Urology, vol. 58, no. 4, pp. 588-595, 2009.
25. S. Waalkes, F. Becker, A. J. Schrader et al., "Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNMversion" European Urology, vol. 59, no. 2, pp. 258-263, 2011.
26. J. Bedke, S. Buse, M. Pritsch et al., "Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences," BJU International, vol. 103, no. 10, pp. 1349-1354, 2009.
27. J. R. Srigley, B. Delahunt, J. N. Eble et al., "The International Society ofUrological Pathology (ISUP)Vancouver classification of renal neoplasia," American Journal of Surgical Pathology, vol. 37, no. 10, pp. 1469-1489, 2013.
28. K. A. Keegan, C. W. Schupp, K. Chamie, N. J. Hellenthal, C. P. Evans, and T. M. Koppie, "Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage," Journal of Urology, vol. 188, no. 2, pp. 391-397, 2012.
29. W. R. Sukov, C. M. Lohse, B. C. Leibovich, R. H. Thompson, and J. C. Cheville, "Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma," Journal of Urology, vol. 187, no. 1, pp. 54-59, 2012.
30. G. P. Paner, M. B. Amin, I. Alvarado-Cabrero et al., "A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with fuhrman nuclear grade," The American Journal of Surgical Pathology, vol. 34, no. 9, pp. 1233-1240, 2010.
31. A. Kutikov and R. G. Uzzo, "TheR. E. N. A. L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth," Journal of Urology, vol. 182, no. 3, pp. 844-853, 2009.
32. S. MacLennan, M. Imamura, M. C. Lapitan et al., "Systematic review of oncological outcomes following surgicalmanagement of localised renal cancer," European Urology, vol. 61, no. 5, pp. 972-993, 2012.
33. V. Ficarra, G. Novara, S. Secco et al., "Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephronsparing surgery," European Urology, vol. 56, no. 5, pp. 786-793, 2009.
34. M. N. Simmons, C. B. Ching, M. K. Samplaski, C. H. Park, and I. S. Gill, "Kidney tumor locationmeasurement using the C index method," The Journal of Urology, vol. 183, no. 5, pp. 1708-1713, 2010.
35. H.-J. Tan, J. S. Wolf Jr., Z. Ye, J. T. Wei, and D. C. Miller, "Population-level comparative effectiveness of laparoscopic versus open radical nephrectomy for patients with kidney cancer," Cancer, vol. 117, no. 18, pp. 4184-4193, 2011.
36. S. MacLennan, M. Imamura, M. C. Lapitan et al., "Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer," European Urology, vol. 62, no. 6, pp. 1097-1117, 2012.
37. H. J. Bekema, S. MacLennan, M. Imamura et al., "Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma," European Urology, vol. 64, no. 5, pp. 799-810, 2013.
38. J. H. M. Blom, H. van Poppel, J. M. Maréchal et al., "Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881," European Urology, vol. 55, no. 1, pp. 28-34, 2009.
39. J. Usui, I. G. Glezerman, S. P. Salvatore, C. B. Chandran, C. D. Flombaum, and S. V. Seshan, "Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature," Human Pathology, vol. 45, no. 9, pp. 1918-1927, 2014.
40. B. Escudier, L. Albiges, and G. Sonpavde, "Optimal management of metastatic renal cell carcinoma: current status," Drugs, vol. 73, no. 5, pp. 427-438, 2013.
41. D. F. McDermott, "Immunotherapy of metastatic renal cell carcinoma," Cancer, vol. 115, supplement 10, pp. 2298-2305, 2009.
42. P. I. Karakiewicz, A. Briganti, F. K.-H. Chun et al., "Multiinstitutional validation of a new renal cancer-specific survival nomogram," Journal of Clinical Oncology, vol. 25, no. 11, pp. 1316-1322, 2007.
43. R. Zigeuner, G. Hutterer, T. Chromecki et al., "External validation of theMayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology," European Urology, vol. 57, no. 1, pp. 102-111, 2010.
44. H. Isbarn and P. I. Karakiewicz, "Predicting cancer-control outcomes in patients with renal cell carcinoma," Current Opinion in Urology, vol. 19, no. 3, pp. 247-257, 2009.
45. P. I. Karakiewicz, N. Suardi, U. Capitanio et al., "A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma," European Urology, vol. 55, no. 2, pp. 287-295, 2009.
46. C. Eichelberg, K. Junker, B. Ljungberg, and H. Moch, "Diagnostic and prognostic molecular marker for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability," European Urology, vol. 55, no. 4, pp. 851-863, 2009.
47. J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin, "Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials," Clinical Cancer Research, vol. 13, no. 2, pp. 703s-708s, 2007.
48. T. Kondo, "Inconvenient truth: Cancer biomarker development by using proteomics," Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1844, no. 5, pp. 861-865, 2014.
49. S. Gupta, A. Venkatesh, S. Ray, and S. Srivastava, "Challenges and prospects for biomarker research: a current perspective from the developing world," Biochimica et Biophysica Acta, vol. 1844, no. 5, pp. 899-908, 2014.
50. E. Rodrguez-Suárez, J. Siwy, P. Zürbig, and H. Mischak, "Urine as a source for clinical proteome analysis: from discovery to clinical application," Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1844, no. 5, pp. 884-898, 2014.
51. R. Rajandram, N. Y. Yap, J. Pailoor et al., "Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal," Pathology, vol. 46, no. 6, pp. 518-522, 2014.
52. M. Katsogiannou, C. Andrieu, and P. Rocchi, "Heat shock protein 27 phosphorylation state is associated with cancer progression," Frontiers in Genetics, vol. 5, article 346, 2014.
53. N. M. A. White, O. Masui, L. V. DeSouza et al., "Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma," Oncotarget, vol. 5, no. 2, pp. 506-518, 2014.
54. A. R. de Vivar Chevez, J. Finke, and R. Bukowski, "The Role of Inflammation in Kidney Cancer," in Inflammation and Cancer, vol. 816 of Advances in Experimental Medicine and Biology, pp. 197-234, Springer, Basel, Switzerland, 2014.
55. A. Mittal, B. Poudel, D. R. Pandeya, S. P. Gupta, B. Sathian, and S. K. Yadav, "Serum amyloid a as an independent prognostic factor for renal cell carcinoma-a hospital based study from the western region of nepal," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2253-2255, 2012.
56. K. Fischer, G. Theil, R. Hoda, and P. Fornara, "Serum amyloid A: a biomarker for renal cancer," Anticancer Research, vol. 32, no. 5, pp. 1801-1804, 2012.
57. M. deMartino, T. Klatte,C. Seemann et al., "Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)," BJU International, vol. 111, no. 8, pp. E348-E353, 2013.
58. S. Steffens, A. Köhler, R. Rudolph et al., "Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients," BMC Cancer, vol. 12, article 399, 2012.
59. A. Corti, M. Franzini, A. Paolicchi, and A. Pompella, "Gammaglutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting," Anticancer Research, vol. 30, no. 4, pp. 1169-1181, 2010.
60. S. L. Hofbauer, K. I. Stangl,M. deMartino et al., "Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma," British Journal of Cancer, vol. 111, no. 8, pp. 1526-1531, 2014.
61. R. S. Wong, "Apoptosis in cancer: from pathogenesis to treatment," Journal of Experimental & Clinical Cancer Research, vol. 30, article 87, 2011.
62. F. Wang, J. Lin, and R. Xu, "The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs," Current Pharmaceutical Design, vol. 20, no. 42, pp. 6714-6122, 2014.
63. D. Toiyama, N. Takaha, M. Shinnoh et al., "Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma," Molecular and Clinical Oncology, vol. 1, no. 1, pp. 69-74, 2013.
64. F. Tas, S. Karabulut, I. Yildiz, and D. Duranyildiz, "Clinical significance of serum M30 and M65 levels in patients with breast cancer," Biomedicine & Pharmacotherapy, vol. 68, no. 8, pp. 1135-1140, 2014.
65. I. Yildiz, F. Sen, L. Kilic et al., "Serum m65 as a biomarker for metastatic renal cell carcinoma," Clinical Genitourinary Cancer, vol. 11, no. 3, pp. 290-296, 2013.
66. I. J. Frew and H. Moch, "A clearer view of the molecular complexity of clear cell renal cell carcinoma," Annual Review of Pathology, vol. 10, no. 1, pp. 263-289, 2015.
67. T. Tanaka, H. Kitamura, T. Torigoe et al., "Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5,pp. 789-794, 2011.
68. J. Pastorek and S. Pastorekova, "Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use," Seminars in Cancer Biology, vol. 31,pp. 52-64, 2015.
69. M. Takacova,M. Bartosova, L. Skvarkova et al., "Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma," Oncology Letters, vol. 5, no. 1, pp. 191-197, 2013.
70. B. Nisman, V. Yutkin, H. Nechushtan et al., "Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy," Urology, vol. 76, no. 2, pp. 513. e1-513. e6, 2010.
71. P. D'Arcy, X. Wang, and S. Linder, "Deubiquitinase inhibition as a cancer therapeutic strategy," Pharmacology &Therapeutics, vol. 147, pp. 32-54, 2015.
72. M. deMartino, K. Hoetzenecker, H. J. Ankersmit et al., "Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis," British Journal of Cancer, vol. 106, no. 5, pp. 904-908, 2012.
73. F. P. Schena, F. P. Selvaggi, L. Gesualdo, and M. Battaglia, Malattie del rene e delle vie urinarie, McGraw-Hill, 4th edition, 2008.
74. K. Papworth, A. Bergh, K. Grankvist, B. Ljungberg, J. Sandlund, and T. Rasmuson, "Osteopontin but not parathyroid hormonerelated protein predicts prognosis in human renal cell carcinoma," Acta Oncologica, vol. 52, no. 1, pp. 159-165, 2013.
75. A. di Carlo, D. Terracciano, A. Mariano, A. Oliva, M. D'Armiento, and V. Macchia, "Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors," International Journal of Oncology, vol. 23, pp. 757-762, 2003.
76. K. Kaya, S. Ayan, G. Gokce, H. Kilicarslan, E. Yildiz, and E. Y. Gultekin, "Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma," Scandinavian Journal of Urology and Nephrology, vol. 39, no. 1, pp. 25-29, 2005.
77. G. Ozer, M. Altinel, B. Kocak, A. Yazicioglu, and F. Gonenc, "Value of urinary NMP-22 in patients with renal cell carcinoma," Urology, vol. 60, no. 4, pp. 593-597, 2002.
78. S. Huang, E. Rhee, H. Patel, E. Park, and J. Kaswick, "Urinary NMP-22 and renal cell carcinoma," Urology, vol. 55, no. 2, pp. 227-230, 2000.
79. D. R. Flower, "The lipocalin protein family: structure and function," Biochemical Journal, vol. 318, no. 1, pp. 1-14, 1996.
80. A. Di Carlo, "The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias," Prevention & Reseatch, vol. 2, 2012.
81. L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses, "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL,"The Journal of Biological Chemistry, vol. 276, no. 40, pp. 37258-37265, 2001.
82. A. Di Carlo, "Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors," Oncology Letters, vol. 5, no. 5, pp. 1677-1681, 2013.
83. J. J. Morrissey, A. N. London, M. C. Lambert, and E. D. Kharasch, "Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma," The American Journal of Nephrology, vol. 34, no. 5, pp. 391-398, 2011.
84. A. di Carlo, "Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma," Oncology Reports, vol. 28, no. 3, pp. 1051-1056, 2012.
85. J. J. Morrissey, A. N. London, J. Luo, and E. D. Kharasch, "Urinary biomarkers for the early diagnosis of kidney cancer," Mayo Clinic Proceedings, vol. 85, no. 5, pp. 413-421, 2010.
86. J. J. Morrissey and E. D. Kharasch, "The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma," Journal of Urology, vol. 189, no. 5, pp. 1913-1920, 2013.
87. J. J. Morrissey, J. Mobley, J. Song et al., "Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade," Urology, vol. 83, no. 1, pp. 256. e9-256. e14, 2014.